WellPoint Will Put Comparative Effectiveness Guidance In Updated Drug Assessment Criteria
This article was originally published in The Pink Sheet Daily
Executive Summary
The health insurer's next iteration of its technology assessment criteria, used for evaluating drugs for formulary inclusion, will likely be published by the end of the year.
You may also be interested in...
WellPoint's Comparative Effectiveness Research Guidelines Describe How It Will Determine Usefulness Of Studies
The largest provider of health benefits in the U.S. will use the CER guidelines when evaluating drugs for its formulary.
WellPoint's Comparative Effectiveness Research Guidelines Describe How It Will Determine Usefulness Of Studies
The largest provider of health benefits in the U.S. will use the CER guidelines when evaluating drugs for its formulary.
Senate Considers Revised Comparative Effectiveness Plan In Reform Bill
Comparative effectiveness research led by a non-government institute with funding from public and private sources, as envisioned by Sen. Max Baucus, D-Mont., is among the provisions for health care reform that are being debated by the Senate, but some changes to CER provisions were made as the bill moved from the Finance Committee to its current iteration on the Senate floor